Myelodysplastic Syndromes An Issue of Hematology/Oncology Clinics of North America, 1st Edition
Author :
David Steensma
Date of Publication: 03/2020
This issue of Hematology/Oncology Clinics, guest edited by David P. Steensma, will cover key topics in Myelodysplastic Syndromes. This issue is one of six selected each year by our series consulting editors, George P. Canellos and Edward J. Benz. Top ...view more
This issue of Hematology/Oncology Clinics, guest edited by David P. Steensma, will cover key topics in Myelodysplastic Syndromes. This issue is one of six selected each year by our series consulting editors, George P. Canellos and Edward J. Benz. Topics discussed in this issue will include: Novel prognostic models for MDS, Evaluating MDS patients with genetic mutations that might be germline, Implications of splicing mutations in MDS for pathophysiology and therapy, Assessing quality of life in MDS/MPN overlap patients, Creation of a clinic for patients with clonal hematopoiesis, Luspatercept in MDS, Prospects for venetoclax in MDS, Treatment of acquired sideroblastic anemias, Treatment of patients with AML arising from MDS, Targeting TP53 mutations in MDS, among others.
This issue of Hematology/Oncology Clinics, guest edited by David P. Steensma, will cover key topics in Myelodysplastic Syndromes. This issue is one of six selected each year by our series consulting editors, George P. Canellos and Edward J. Benz. Topics discussed in this issue will include: Novel prognostic models for MDS, Evaluating MDS patients with genetic mutations that might be germline, Implications of splicing mutations in MDS for pathophysiology and therapy, Assessing quality of life in MDS/MPN overlap patients, Creation of a clinic for patients with clonal hematopoiesis, Luspatercept in MDS, Prospects for venetoclax in MDS, Treatment of acquired sideroblastic anemias, Treatment of patients with AML arising from MDS, Targeting TP53 mutations in MDS, among others.
Bring it with you - The Bookshelf app allows you to access books on your laptop, tablet or mobile, so your ebooks go where ever you are - online or offline.
Take notes - Highlight, bookmark and take notes and highlights automatically stay in sync no matter where you make them.
Listen to eBooks - When you need to go screenless, the Text-to-speech tool will read your book aloud.
Powerful search - The searching capabilities allow you to search keywords through all your eBooks, the entire Bookshelf Library and well as on Wikipedia.
Ecological - Manage your environmental impact with paperless books.
How to read your VitalSource eBooks
Purchase your VitalSource eBook on the Elsevier Health site
https://www.uk.elsevierhealth.com/myelodysplastic-syndromes-an-issue-of-hematologyoncology-clinics-of-north-america-9780323722599.html82748Myelodysplastic Syndromes An Issue of Hematology/Oncology Clinics of North Americahttps://www.uk.elsevierhealth.com/media/catalog/product/9/7/9780323722599_5.jpg73.7981.99GBPInStock/Medicine and Surgery/Haematology/Books/Clinics Review Articles100335255039561283917453100005145120This issue of Hematology/Oncology Clinics, guest edited by David P. Steensma, will cover key topics in Myelodysplastic Syndromes. This issue is one of six selected each year by our series consulting editors, George P. Canellos and Edward J. Benz. Topics discussed in this issue will include: Novel prognostic models for MDS, Evaluating MDS patients with genetic mutations that might be germline, Implications of splicing mutations in MDS for pathophysiology and therapy, Assessing quality of life in MDS/MPN overlap patients, Creation of a clinic for patients with clonal hematopoiesis, Luspatercept in MDS, Prospects for venetoclax in MDS, Treatment of acquired sideroblastic anemias, Treatment of patients with AML arising from MDS, Targeting TP53 mutations in MDS, among others. This issue of Hematology/Oncology Clinics, guest edited by David P. Steensma, will cover key topics in Myelodysplastic Syndromes. This issue is one of six selected each year by our series consulting editors, George P. Canellos and Edward J. Benz. Topics discussed in this issue will include: Novel prognostic models for MDS, Evaluating MDS patients with genetic mutations that might be germline, Implications of splicing mutations in MDS for pathophysiology and therapy, Assessing quality of life in MDS/MPN overlap patients, Creation of a clinic for patients with clonal hematopoiesis, Luspatercept in MDS, Prospects for venetoclax in MDS, Treatment of acquired sideroblastic anemias, Treatment of patients with AML arising from MDS, Targeting TP53 mutations in MDS, among others.00add-to-cart97803237225992020ProfessionalBy David Steensma20201Book152w x 229h (6.00" x 9.00")Elsevier2404 Mar 2020PRINT ON DEMAND - DELIVERY CAN TAKE UP TO 10 DAYSBy <STRONG>David Steensma</STRONG>ClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select
